55 related articles for article (PubMed ID: 32175105)
1. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia.
Rogers JE; Mizrahi JD; Shroff RT; Nelson DA; Tu J; Javle MM; Wolff RA; Pant S
J Gastrointest Oncol; 2020 Feb; 11(1):55-60. PubMed ID: 32175105
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer.
Petrioli R; Torre P; Pesola G; Paganini G; Paolelli L; Miano ST; Martellucci I; Francini G; Francini E
J Geriatr Oncol; 2020 May; 11(4):647-651. PubMed ID: 31471168
[TBL] [Abstract][Full Text] [Related]
3. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
[TBL] [Abstract][Full Text] [Related]
5. FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer.
Catalano M; Conca R; Petrioli R; Ramello M; Roviello G
Cancer Manag Res; 2020; 12():10271-10278. PubMed ID: 33116881
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant nab-paclitaxel plus gemcitabine
Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
[TBL] [Abstract][Full Text] [Related]
7. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain.
Yeh C; Bates SE
Semin Oncol; 2021 Feb; 48(1):34-46. PubMed ID: 33712267
[TBL] [Abstract][Full Text] [Related]
8. French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel
Demaziere A; Mourgues C; Lambert C; Trevis S; Bertucat H; Grange I; Pezet D; Sautou V; Jary M; Gagnière J
Ther Adv Med Oncol; 2024; 16():17588359241259635. PubMed ID: 38882442
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison.
Kharat A; Brendle M; Chhibber A; Chaiyakunapruk N; Biskupiak J
Oncol Res Treat; 2021; 44(9):476-484. PubMed ID: 34315166
[TBL] [Abstract][Full Text] [Related]
10. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.
Ahn DH; Krishna K; Blazer M; Reardon J; Wei L; Wu C; Ciombor KK; Noonan AM; Mikhail S; Bekaii-Saab T
Ther Adv Med Oncol; 2017 Feb; 9(2):75-82. PubMed ID: 28203300
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
Front Oncol; 2020; 10():1112. PubMed ID: 32850319
[No Abstract] [Full Text] [Related]
12.
Kim G
Cancer Manag Res; 2017; 9():85-96. PubMed ID: 28356771
[TBL] [Abstract][Full Text] [Related]
13. A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Tachihara M; Kiriu T; Hata A; Hatakeyama Y; Nakata K; Nagano T; Yamamoto M; Kobayashi K; Ohnishi H; Katakami N; Nishimura Y
Cancer Manag Res; 2019; 11():7135-7140. PubMed ID: 31534366
[TBL] [Abstract][Full Text] [Related]
14. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Pusceddu S; Ghidini M; Torchio M; Corti F; Tomasello G; Niger M; Prinzi N; Nichetti F; Coinu A; Di Bartolomeo M; Cabiddu M; Passalacqua R; de Braud F; Petrelli F
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959763
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus
Trestini I; Carbognin L; Peretti U; Sperduti I; Caldart A; Tregnago D; Avancini A; Auriemma A; Orsi G; Pilotto S; Frulloni L; Capurso G; Bria E; Reni M; Tortora G; Milella M
Front Oncol; 2021; 11():688889. PubMed ID: 34568019
[TBL] [Abstract][Full Text] [Related]
17. Second-line systemic treatment for advanced cholangiocarcinoma.
Rogers JE; Law L; Nguyen VD; Qiao W; Javle MM; Kaseb A; Shroff RT
J Gastrointest Oncol; 2014 Dec; 5(6):408-13. PubMed ID: 25436118
[TBL] [Abstract][Full Text] [Related]
18. A case report of surgical resection treatment for complete remission after chemotherapy for advanced pancreatic cancer.
Zhang Z; Lin H; Li H; Wang X
Front Oncol; 2023; 13():1155233. PubMed ID: 37305571
[TBL] [Abstract][Full Text] [Related]
19. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.
Rogers JE; Mizrahi JD; Xiao L; Mohindroo C; Shroff RT; Wolff R; Varadhachary GR; Javle MM; Overman M; Fogelman DR; Raghav KPS; Pant S; McAllister F
Cancer Med; 2020 Aug; 9(15):5406-5415. PubMed ID: 32519420
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
